A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)

Trial Profile

A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Mitomycin (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OPTIMA
  • Sponsors TheraCoat; UroGen Pharma
  • Most Recent Events

    • 01 Apr 2014 Top-line results reported in a TheraCoat media release.
    • 01 Apr 2014 Status changed from recruiting to completed, as reported by a TheraCoat media release.
    • 04 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top